| P50 | author | Paulo Filipe | Q43254235 |
| P2093 | author name string | Manuel Marques Gomes | |
| | Diana Miguel | |
| | Catarina Pinheiro | |
| | João Pedro Freitas | |
| | Luís Uva | |
| P2860 | cites work | Clinical manifestations of cutaneous lupus erythematosus | Q94608586 |
| | Clearance of Apoptotic Cells in Human SLE | Q22306425 |
| | Antileprosy drugs and lupus erythematosus | Q28279221 |
| | The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 |
| | Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 |
| | Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self | Q29619194 |
| | The lupus band: do the autoantibodies target collagen VII? | Q30829032 |
| | Update on the management of cutaneous lupus erythematosus | Q31121574 |
| | Lupus erythematosus in the 1980s: a survey of 570 patients | Q33384712 |
| | JNK mediates hepatic ischemia reperfusion injury | Q44070094 |
| | Oral mucosal ulceration in systemic lupus erythematosus | Q44446036 |
| | c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation | Q45022024 |
| | Systemic lupus erythematosus: a clinical analysis | Q45121430 |
| | Early diagnosis and treatment of discoid lupus erythematosus | Q46098741 |
| | Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. | Q46753315 |
| | Oral mucosal keratinocytes express RANTES and ICAM-1, but not interleukin-8, in oral lichen planus and oral lichenoid reactions induced by amalgam fillings | Q47565621 |
| | Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al. | Q47696967 |
| | Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus | Q47840679 |
| | Photosensitivity in systemic lupus erythematosus: laboratory testing of ARA/ACR definition. | Q50537114 |
| | Efalizumab in the treatment of discoid lupus erythematosus. | Q52853368 |
| | Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). | Q53905611 |
| | Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort | Q33555419 |
| | Autoantibodies against C1q: view on clinical relevance and pathogenic role | Q33597523 |
| | Clinical practice. Raynaud's Phenomenon | Q34151713 |
| | Belimumab: review of use in systemic lupus erythematosus | Q34215264 |
| | Treatment of lichen planus. An evidence-based medicine analysis of efficacy | Q34485885 |
| | Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin | Q34576723 |
| | Hair follicle stem cells in the pathogenesis of the scarring process in cutaneous lupus erythematosus | Q34927694 |
| | Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | Q35047657 |
| | Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. | Q35230924 |
| | Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activ | Q35572124 |
| | Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma | Q35686749 |
| | Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus | Q35764310 |
| | Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism | Q35791634 |
| | Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus | Q35973816 |
| | Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings | Q36180056 |
| | Clinical manifestations of cutaneous lupus erythematosus | Q36180075 |
| | Animal models of spontaneous and drug-induced cutaneous lupus erythematosus | Q36218765 |
| | Pathophysiology of cutaneous lupus erythematosus--novel aspects | Q36599169 |
| | Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. | Q36793158 |
| | International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. | Q36848308 |
| | Diagnostic approach and treatment of cutaneous lupus erythematosus | Q37055239 |
| | Hypocomplementemic urticarial vasculitis in systemic lupus erythematosus | Q37116829 |
| | HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development | Q37765002 |
| | Diagnosis and management of Raynaud's phenomenon | Q37982351 |
| | Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus | Q38009852 |
| | Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets | Q38152168 |
| | The natural history of systemic lupus erythematosus by prospective analysis | Q39866953 |
| | Post-transcriptional regulation of human inducible nitric-oxide synthase expression by the Jun N-terminal kinase. | Q40166757 |
| | Classification and therapy of atrophie blanche | Q40234192 |
| | Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution | Q40614161 |
| | Expression of RANTES and CCR1 in oral lichen planus and association with mast cell migration | Q40743720 |
| | CLINICAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. COMPUTER ANALYSIS OF 520 CASES. | Q40971202 |
| | Gamma-interferon induced human keratinocyte HLA-DR synthesis: the role of dermal activated T lymphocytes | Q41254970 |
| | Quality of life measurement in dermatology: a practical guide | Q41442406 |
| | Atrophie blanche--a special form of vasculopathy | Q41575695 |
| | Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions. | Q41912384 |
| | Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus | Q41977234 |
| | Biological therapy in systemic lupus erythematosus | Q42141973 |
| | Th1 cytokines in oral lichen planus | Q42436081 |
| | T lymphocytes and altered keratinocytes express interferon-gamma and interleukin 6 in lichen planus | Q42479368 |
| | Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus | Q42479840 |
| | Efficacy of sulfasalazine in the treatment of generalized lichen planus: randomized double-blinded clinical trial on 52 patients. | Q43160780 |
| | Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus. | Q54664588 |
| | Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus | Q61050853 |
| | The basement membrane zone in patients with systemic lupus erythematosus: immunofluorescence studies in the skin, kidney and amniochorion. | Q64926573 |
| | Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus | Q66880648 |
| | Livedo vasculitis: vasculitis or thrombotic vasculopathy? | Q67574194 |
| | Atrophie blanche. Clinical diagnosis and treatment | Q67825194 |
| | Pentoxifylline (Trental) therapy for the vasculitis of atrophie blanche | Q70025647 |
| | Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap | Q70226929 |
| | Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy | Q70251379 |
| | Idiopathic atro hie blanche | Q70263899 |
| | Oral mucosal lesions in systemic lupus erythematosus--a clinical, histopathological and immunopathological study | Q70326235 |
| | Antiplatelet therapy in atrophie blanche and livedo vasculitis | Q70483663 |
| | Serum isoamylases in patients with autoimmune rheumatic diseases | Q70765379 |
| | Oral discoid lupus erythematosus. III. A histopathologic study of sixty-six patients | Q70935608 |
| | Minidose heparin therapy for vasculitis of atrophie blanche | Q71667096 |
| | Clinical features of early cases of systemic lupus erythematosus in Iraqui patients | Q71788097 |
| | Palmar Lesions in Lupus Erythematosus | Q72253446 |
| | Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients | Q72477525 |
| | Urticarial vasculitis | Q73385829 |
| | Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus | Q73802358 |
| | Phototesting in lupus erythematosus: a 15-year experience | Q74088240 |
| | The spectrum of cutaneous manifestations in lupus erythematosus--the Italian experience | Q74300477 |
| | Nitric oxide fully protects against UVA-induced apoptosis in tight correlation with Bcl-2 up-regulation | Q74485109 |
| | Oral manifestations in patients with Sjögren's syndrome | Q74582735 |
| | Urticarial vasculitis | Q74765908 |
| | Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus | Q77567399 |
| | Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients | Q77783206 |
| | Lupus panniculitis: clinical perspectives from a case series | Q77904235 |
| | Quantification of regulatory T cells in patients with systemic lupus erythematosus | Q79253319 |
| | Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus | Q80403794 |
| | Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation | Q82704301 |
| | [Diagnosis and treatment of livedo reticularis on the legs] | Q82958664 |
| | Autoimmune bullous dermatoses: a review | Q84565439 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 834291 | |
| P577 | publication date | 2012-07-25 | |
| P1433 | published in | Autoimmune Diseases | Q26842451 |
| P1476 | title | Cutaneous manifestations of systemic lupus erythematosus | |
| P478 | volume | 2012 | |